Prognostic factors and the impact of frontline therapy in peripheral T-cell lymphoma: 10 years of 'real-world' experience from Western Australia

James A. Kuzich, Andrew P. Hutchison, Kenneth J. C. Lim, Portia Smallbone, Kate Denning, Matthew P. Wright, Gavin Cull, Michael F. Leah, David J. L. Joske, Dejan Radeski, Duncan Purtill

Research output: Contribution to journalArticle

Abstract

We present an analysis of 98 consecutive patients with peripheral T-cell lymphoma (PTCL) treated over a 10-year period within Western Australia. The most common frontline therapies were CHO(E)P (47%), HyperCVAD (21%), and reduced intensity therapy or supportive care alone (19%). Median and 4-year overall survival (OS) for the whole cohort were 1.59 years and 34%. Amongst CHO(E)P and HyperCVAD-treated patients, elevated LDH, advanced stage, IPI >1, and non-ALK + ALCL histology predicted inferior progression-free survival (PFS). Inferior OS was predicted by elevated LDH, age >60, IPI >1, and non-ALK + ALCL histology. Response rates and PFS were not significantly different between patients treated with CHO(E)P or HyperCVAD. OS was longer in the HyperCVAD group, however this was not significant on multivariable analysis and appears to relate to the younger age and more aggressive therapy at relapse in this group. Our data confirmed the prognostic utility of the IPI in patients with PTCL and do not demonstrate a clear benefit of HyperCVAD.

Original languageEnglish
Number of pages9
JournalLEUKEMIA & LYMPHOMA
DOIs
Publication statusE-pub ahead of print - Jul 2019

Cite this

Kuzich, James A. ; Hutchison, Andrew P. ; Lim, Kenneth J. C. ; Smallbone, Portia ; Denning, Kate ; Wright, Matthew P. ; Cull, Gavin ; Leah, Michael F. ; Joske, David J. L. ; Radeski, Dejan ; Purtill, Duncan. / Prognostic factors and the impact of frontline therapy in peripheral T-cell lymphoma : 10 years of 'real-world' experience from Western Australia. In: LEUKEMIA & LYMPHOMA. 2019.
@article{46e31ef2897b43e39773bbfd6980f618,
title = "Prognostic factors and the impact of frontline therapy in peripheral T-cell lymphoma: 10 years of 'real-world' experience from Western Australia",
abstract = "We present an analysis of 98 consecutive patients with peripheral T-cell lymphoma (PTCL) treated over a 10-year period within Western Australia. The most common frontline therapies were CHO(E)P (47{\%}), HyperCVAD (21{\%}), and reduced intensity therapy or supportive care alone (19{\%}). Median and 4-year overall survival (OS) for the whole cohort were 1.59 years and 34{\%}. Amongst CHO(E)P and HyperCVAD-treated patients, elevated LDH, advanced stage, IPI >1, and non-ALK + ALCL histology predicted inferior progression-free survival (PFS). Inferior OS was predicted by elevated LDH, age >60, IPI >1, and non-ALK + ALCL histology. Response rates and PFS were not significantly different between patients treated with CHO(E)P or HyperCVAD. OS was longer in the HyperCVAD group, however this was not significant on multivariable analysis and appears to relate to the younger age and more aggressive therapy at relapse in this group. Our data confirmed the prognostic utility of the IPI in patients with PTCL and do not demonstrate a clear benefit of HyperCVAD.",
keywords = "Peripheral T cell lymphoma, international prognostic index, intensive therapy, HyperCVAD, NON-HODGKIN-LYMPHOMA, PHASE-II, COHORT",
author = "Kuzich, {James A.} and Hutchison, {Andrew P.} and Lim, {Kenneth J. C.} and Portia Smallbone and Kate Denning and Wright, {Matthew P.} and Gavin Cull and Leah, {Michael F.} and Joske, {David J. L.} and Dejan Radeski and Duncan Purtill",
year = "2019",
month = "7",
doi = "10.1080/10428194.2019.1637865",
language = "English",
journal = "LEUKEMIA & LYMPHOMA",
issn = "1026-8022",
publisher = "Informa Healthcare USA",

}

Prognostic factors and the impact of frontline therapy in peripheral T-cell lymphoma : 10 years of 'real-world' experience from Western Australia. / Kuzich, James A.; Hutchison, Andrew P.; Lim, Kenneth J. C.; Smallbone, Portia; Denning, Kate; Wright, Matthew P.; Cull, Gavin; Leah, Michael F.; Joske, David J. L.; Radeski, Dejan; Purtill, Duncan.

In: LEUKEMIA & LYMPHOMA, 07.2019.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Prognostic factors and the impact of frontline therapy in peripheral T-cell lymphoma

T2 - 10 years of 'real-world' experience from Western Australia

AU - Kuzich, James A.

AU - Hutchison, Andrew P.

AU - Lim, Kenneth J. C.

AU - Smallbone, Portia

AU - Denning, Kate

AU - Wright, Matthew P.

AU - Cull, Gavin

AU - Leah, Michael F.

AU - Joske, David J. L.

AU - Radeski, Dejan

AU - Purtill, Duncan

PY - 2019/7

Y1 - 2019/7

N2 - We present an analysis of 98 consecutive patients with peripheral T-cell lymphoma (PTCL) treated over a 10-year period within Western Australia. The most common frontline therapies were CHO(E)P (47%), HyperCVAD (21%), and reduced intensity therapy or supportive care alone (19%). Median and 4-year overall survival (OS) for the whole cohort were 1.59 years and 34%. Amongst CHO(E)P and HyperCVAD-treated patients, elevated LDH, advanced stage, IPI >1, and non-ALK + ALCL histology predicted inferior progression-free survival (PFS). Inferior OS was predicted by elevated LDH, age >60, IPI >1, and non-ALK + ALCL histology. Response rates and PFS were not significantly different between patients treated with CHO(E)P or HyperCVAD. OS was longer in the HyperCVAD group, however this was not significant on multivariable analysis and appears to relate to the younger age and more aggressive therapy at relapse in this group. Our data confirmed the prognostic utility of the IPI in patients with PTCL and do not demonstrate a clear benefit of HyperCVAD.

AB - We present an analysis of 98 consecutive patients with peripheral T-cell lymphoma (PTCL) treated over a 10-year period within Western Australia. The most common frontline therapies were CHO(E)P (47%), HyperCVAD (21%), and reduced intensity therapy or supportive care alone (19%). Median and 4-year overall survival (OS) for the whole cohort were 1.59 years and 34%. Amongst CHO(E)P and HyperCVAD-treated patients, elevated LDH, advanced stage, IPI >1, and non-ALK + ALCL histology predicted inferior progression-free survival (PFS). Inferior OS was predicted by elevated LDH, age >60, IPI >1, and non-ALK + ALCL histology. Response rates and PFS were not significantly different between patients treated with CHO(E)P or HyperCVAD. OS was longer in the HyperCVAD group, however this was not significant on multivariable analysis and appears to relate to the younger age and more aggressive therapy at relapse in this group. Our data confirmed the prognostic utility of the IPI in patients with PTCL and do not demonstrate a clear benefit of HyperCVAD.

KW - Peripheral T cell lymphoma

KW - international prognostic index

KW - intensive therapy

KW - HyperCVAD

KW - NON-HODGKIN-LYMPHOMA

KW - PHASE-II

KW - COHORT

U2 - 10.1080/10428194.2019.1637865

DO - 10.1080/10428194.2019.1637865

M3 - Article

JO - LEUKEMIA & LYMPHOMA

JF - LEUKEMIA & LYMPHOMA

SN - 1026-8022

ER -